Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

BACKGROUND AND OBJECTIVE: Tirzepatide, a novel, once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is approved in the US as a treatment for type 2 diabetes and is under development for long-term weight management, heart failure with preserved...

Descripción completa

Detalles Bibliográficos
Autores principales: Urva, Shweta, Quinlan, Tonya, Landry, John, Ma, Xiaosu, Martin, Jennifer A., Benson, Charles T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287213/
https://www.ncbi.nlm.nih.gov/pubmed/35674880
http://dx.doi.org/10.1007/s40262-022-01140-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287213/
https://www.ncbi.nlm.nih.gov/pubmed/35674880
http://dx.doi.org/10.1007/s40262-022-01140-3

Ejemplares similares